Summary
It could be shown that the post mortem analysis of biogenic amines, precursors, and metabolites in the human brain are influenced by various parameters.
-
1.
The patient's medical history; long term observation of the course of the disease; age; sex.
-
2.
Terminal illness; duration of terminal illness.
-
3.
Previous treatment with drugs; last drugs.
-
4.
Time interval between last drug treatment and death; time of day and date of last drug consumption.
-
5.
Rapidity of death; time of death; duration of coma.
-
6.
Changes occurring in tissues before death; patient's constitution during terminal illness.
-
7.
Changes in concentration of the biogenic amines, precursors, and metabolites depending on the patient's age.
-
8.
Time between death and necropsy.
-
9.
Dissection of specimen.
-
10.
Period of storage; temperature of storage.
-
11.
Chronobiological rhythm of substances.
-
12.
Methods of assay.
-
13.
Homogeneity of all mentioned parameters in the control group and patient group.
For the first time it could be demonstrated that the time course of nigrostriatal degeneration, independent of the age of the parkinsonian at the beginning of the illness, is linear for the last stage and the denervation progressively increases as the duration of illness progresses.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Anton, A. H., Sayre, D. F.: The Distribution of Dopamine and Dopa in Various Animals and a Method for their Determination in Diverse Biological Material. J. Pharmacol. Exp. Ther.145, 326–336 (1964).
Aschoff, J., Ceresa, F., Halberg, F.: Chronobiological Aspects of Endocrinology. Symposia Medica Hoechst 9, Symposium Capri, April 8–10, 1974. Stuttgart-New York: F. K. Schattauer.
Ashcroft, G. W., Sharman, F. D.: Drug Induced Changes in the Concentration of 5-OR Indolyl Compounds in the Cerebrospinal Fluid and Caudate Nucleus. Brit. J. Pharmacol.19, 153–160 (1962).
Bartholini, G., Da Prada, M., Pleischer, A.: Decrease of Cerebral 5-Hydroxytryptamine by 3, 4-Dihydrophenylalanine after Inhibition of Extracerebral Decarboxylase. J. Pharm. Pharmac.20, 228–229 (1968).
Bartholini, G., Lloyd, K. G., Fletscher, A.: Regional Distribution of Catecholmines in Rat Brain after L-3-O-Methyldopa and L-Dopa. Life Sciences14, 323–328 (1974).
Bernheimer, H., Birkmayer, W., Hornykiewicz, O.: Verteilung des 5-Hydroxytryptamins (Serotonin) im Gehirn des Menschen und sein Verhalten bei Patienten mit Parkinson-Syndrom. Klin. Wschr.39, 1056 to 1059 (1961).
Bertler, A., Carlsson, A., Rosengren, E.: A Method for the Fluorometric Determination of Adrenaline and Noradrenaline in Tissues. Acta Physiol. Scand.44, 273–292 (1958).
Birkmayer, W., Hornykiewicz, O.: Der Dioxyphenylalanin (L-Dopa) Effekt beim Parkinson-Syndrom des Menschen. Arch. Psych.203, 560 to 571 (1962).
Birkmayer, W., Danielczyk, W., Neumayer, E., Riederer, P.: The Balance of Biogenic Amines as Condition for Normal Behaviour. J. Neural Transm.33, 163–178 (1972).
Birkmayer, W., Neumayer, E.: Die moderne medikamentöse Behandlung des Parkinsonismus. Z. Neurol.202, 257–280 (1972).
Birkmayer, W., Danielczyk, W., Neumayer, E., Riederer, P.: Nucleus Ruber and L-Dopa Psychosis: Biochemical Post-Mortem Findings. J. Neural Transm.35, 93–116 (1974).
Birkmayer, W., Ambrozi, L., Neumayer, E., Riederer, P.: Longevity in Parkinson's Disease Treated with L-Dopa. Clin. Neurol. Neurosurg.1 (1), 15–19 (1974).
Birkmayer, W., Riederer, P.: Biochemical Post-Mortem Findings in Depressed Patients. J. Neural Transm.37, 95–109 (1975).
Birkmayer, W., Riederer, P., Youdim, M. B. H., Linauer, W.: The Potentiation of the Anti Akinetic Effect after L-Dopa Treatment by an Inhibitor of MAO-B, Deprenil. J. Neural Transm.36, 303–326 (1975).
Birkmayer, W., Hornykiewicz, O.: Advances in Parkinsonism. Editiones Roche. 1976 (in press).
Birkmayer, W., Danielczyk, W., Neumayer, E., Riederer, P.: Serotonin and Extrapyramidal Disorders. In: Serotonin in Mental Abnormalities (Boullin, D. J., ed.). Chichester, England: J. Wiley. 1976 (in press).
Black, I. B., Geen, S. C.: Postmortem Changes in Brain Catecholamine Enzymes. Arch. Neurol.32, 47–49 (1975).
Blinkov, S. M., Glezer, I. I.: Das Zentralnervensystem in Zahlen und Tabellen. Jena: VEB G. Fischer. 1968.
Bogdanski, D. F., Weissbach, H., Udenfriend, S.: The distribution of serotonin, 5-hydroxytryptophan decarboxylase, and monoamine oxidase in brain. J. Neurochem.1, 272–277 (1957).
Bonnycastle, D. D., Bonnycastle, M. F., Anderson, E. G.: The Effect of a Number of Central Depressant Drugs upon Brain 5-Hydroxytryptamine Levels in the Rat. J. Pharm. Exp. Ther.135, 17–20 (1962).
Butcher, L. L., Engel, J.: Behavioral and Biochemical Effects of L-Dopa after Peripheral Decarboxylase Inhibition. Brain Res.15, 233 (1969).
Carlsson, A., Lindqvist, M., Magnusson, T., Waldeck, B.: On the presence of 3-hydroxytryptamine in brain. Science137, 471–473 (1958).
Carlsson, A.: The “On-Of” Effect. Advances in Neurology (McDowell, F., Barbeau, A., eds.), Vol. 5, pp. 367–368. New York: Raven Press. 1974.
Carlsson, A., Lindqvist, M., Kehr, W.: Postmortal Accumulation of 3-Methoxytyramine in Brain. Naunyn-Schmiedeberg's Arch. Pharmacol.284, 365–372 (1974).
Carlsson, A.: V. Int. Symp. on Parkinsons Disease, 13.–17. Sept. 1975, Vienna (in press).
Coyle, J. T., Snyder, S. H.: Antiparkinsonian drugs: inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action. Science166, 899–901 (1969).
Davidson, L., Lloyd, K., Dankova, J., Hornykiewicz, O: L-Dopa Treatment in Parkinson's Disease: Effect on Dopamine and Related Substances in Discrete Brain Regions. Experientia27/9, 1048–1049 (1971).
Dominic, J. A.: Suppression of Brain Serotonin synthesis and Metabolism by Benzodiazepine minor Tranquilizers. In: Serotonin and Behavior (Barchas, J., Usain, E., eds.), pp. 149–155. New York-London: Academic Press. 1973.
Dowson, J. H.: The significance of brain-amine concentrations. The Lancet1969, 596–597.
Everett, G. M., Borcherding, J. W.: L-Dopa: Effect on Concentrations of Dopamine, Norepinephrine and Serotonin in Brains of Mice. Science6, 849–850 (1970).
Ganrot, P. O., Rosengren, E., Gottfries, C. G.: Effect of Iproniazid on Monoamines and Monoamine Oxidase in Human Brain. Experientia18, 260–261 (1962).
Goodwin, F. K., Post, R. M.: Brain Serotonin, Affective Illness and Antidepressiant Drugs: Cerebrospinal Fluid Studies with Probenecid. Adv. in Biochem. Psychopharm., Vol. 11, pp. 341–355. In: Serotonin-New Vistas (Costa, E., Gessa, G. L., Sandler, M., eds.). New York: Raven Press. 1974.
Gottfries, C. G., Oreland, L., Wiberg, A., Winblad, B.: Lowered monoamine oxidase activity in brains from alcoholic suicides. J. of Neurochemistry25, 667–673 (1975).
Joyce, D.: Changes in the 5-hydroxytryptamine content of rat, rabbit and human Brain after death. Brit. J. Pharmacol.18, 370–380 (1962).
Kaiser, R.: Chromatographie in der Gasphase. B. I. Hochschultaschenbücher I—V. Mannheim-Wien-Zürich: Bibliographisches Institut. 1964.
Lajtha, Abel, Toth, J.: Postmortem changes in the cerebral free amino acid pool. Brain Research76, 546–551 (1974).
Lang, H., Rick, W., Róka, L.: Optimierung der Diagnostik. Deutsche Gesellschaft für Klinische Chemie, Merck Symposium, 1973. Berlin-Heidelberg-New York: Springer.
Lloyd, K. G., Farley, I. J., Deck, J. H. N., Hornykiewicz, O.: Serotonin and 5-Hydroxyindoleacetic Acid in Discrete Areas of the Brainstem of Suicide Victrims and Control Patients. Adv. in Biochem. Psychopharmacology11, 387–397 (1974).
Maclean, R., Nicholson, W. J., Pare, C. M. B., Stacey, R. S.: Effect of monoamine-oxidase inhibitors in the concentrations of 5-hydroxytryptamine in the human brain. The Lancet1965, 205–208.
Marley, E., Stephenson, J. D.: Central action of catecholamines. In: Catecholamines (Blaschko, H., Muscholl, E., eds.), Chapter 12, pp. 463 to 537. Berlin-Heidelberg-New York: Springer. 1972.
McGeer, E. G., McGeer, P. L., Wada, J. A.: Distribution of tyrosine hydroxylase in human and animal brain. J. of Neurochemistry18, 1647 to 1658 (1971).
Neumayer, E., Riederer, P., Danielczyk, W., Seemann, D.: Biochemische Hirnbefunde bei endogener Depression. Wr. Med. Wschr.21, 344–349 (1975).
Ng, K. Y., Chase, T. N., Colburn, R. W., Kopin, I. J.: L-Dopa-Induced Release of Cerebral Monoamines. Science170, 76–77 (1970).
Okada, T., Fujita, T., Obta, T., Kato, T., Ikuta, K., Nagatsu, T.: A 24-Hour Rhythm in Human Serum Dopamine-β-Hydroxylase Activity. Specialia1974, 605–607.
Pengelley, Eric T.: Circannual Clocks. New York-San Francisco-London: Academic Press. 1974.
Perry, T. L., Berry, K., Hansen, S., Diamond, S., Mok, C.: Regional distribution of amino acids in human brain obtained at autopsy. J. of Neurochemistry18, 513–519 (1971).
Post, M. E., Sun, A. Y.: The Effect of Chronic Ethanol Administration on the Levels of Catecholamines in Different Regions of the Rat Brain. Res. Comm. Chem. Path. Pharmacol.6 (3), 887–894 (1973).
Quay, W. B.: Differential Extractions for the Spectrophotofluorometric Measurement of Diverse 5-Hydroxy- and 5-Methoxyindoles. Anal. Biochem.5, 51–59 (1963).
Quay, W. B.: Circadian and estrous rhythms in pineal melatonin and 5-hydroxyindole-3-acetic acid. Proc. Soc. Exp. Biol. Med.115, 710–713 (1964).
Reinberg, A.: Aspects of circannual rhythms in man. In: Circannual Clocks (Pengelley, E. T., ed.), pp. 423–505. New York-San Francisco-London: Academic Press. 1974.
Riederer, P., Birkmayer, W., Neumayer, E., Ambrozi, L., Linauer, W.: The Daily Rhythm of HVA, VMA, (VA) and 5-HIAA in Depressionsyndrom. J. Neural Transm.35, 23–45 (1974).
Riederer, P.: to be published (1976).
Rinne, U. K., Sonninen, V., Hyyppä, M.: Effect of L-Dopa on brain monoamines and their metabolites in Parkinson's disease. Life Sciences10, 549–557 (1971).
Robinson, D. S., Davis, J. M., Nies, A., Ravaris, C. L., Sylwester, D.: Relation of Sex and Aging to Monoamine Oxidase Activity of Human Brain, Plasma, and Platelets. Arch. Gen. Psychiat.24, 536–539 (1971).
Robinson, D. S.: Changes in monoamine oxidase and monoamines with human development and aging. Federation Proceedings34, 103–107 (1975).
Saito, Y., Yamashita, I., Yamazaki, K., Okada, F., Satomi, R., Fujieda, T.: Circadian fluctuation of brain acetylcholine in rats. Life Sciences16, 281–288 (1975).
Sandler, M., Bonham-Carter, S., Cuthbert, M. T., Pare, C. M. B.: Is there an increase in monoamine oxidase activity in depressive illness? LancetII, 1045–1047 (1975).
Tagliamonte, A., Cessa, R., Biggio, G., Vargiu, L., Gessa, G. L.: Daily changes of free serum tryptophan in humans. Life Sciences14, 349–354 (1974).
Udenfriend, S.: Fluorescence Assay in Biology and Medicine. New York-London: Academic Press. Vol. I: 1962; Vol. II: 1969.
Wurtman, R. J., Fernstrom, J. D.: Control of Brain Serotonin by the Diet. In: Adv. in Neurology (McDowell, F., Barbeau, A., eds.), Vol. 5, pp. 19 to 29. New York: Raven Press. 1974.
Author information
Authors and Affiliations
Additional information
Dedicated to ProfessorW. Birkmayer, M.D., on the occasion of his 65th birthday.
Rights and permissions
About this article
Cite this article
Riederer, P., Wuketich, S. Time course of nigrostriatal degeneration in parkinson's disease. J. Neural Transmission 38, 277–301 (1976). https://doi.org/10.1007/BF01249445
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01249445